Dendreon (DNDN) Receives Patent for Provenge

As an update to the previous post about Dendreon and it's Cancer drug Provenge, Dendreon just received a European patent for Provenge. Dendreon continues to achieve regulatory approval in the United States first, this news of a European patent opens the door to apply for approval in Europe, which I think greatly increases the value of this stock.

In my opinion, the European Community may be more receptive to new treatments, not stuck in the stone age like the FDA in America.

The FDA recently issued a third approvable letter to Encysive's (ENCY) Thelin, which already has marketing approval in Europe.

Dendreon is still one I like for the risk-reward.